Blog

Welcome to OncLive®’s OncFive!

Every week, we bring you a quick roundup of the 5 top stories from the world of oncology—ranging from pivotal regulatory decisions to key pipeline updates to expert insights on breakthroughs that are moving the needle in cancer care. This resource is designed to keep you informed on the latest updates in the space, in just a matter of minutes.

Here’s what you may have missed this week:

The FDA cleared cemiplimab-rwlc (Libtayo) for adjuvant use in adult patients with cutaneous squamous cell carcinoma (CSCC) at high risk of recurrence after surgery and radiation. The decision was supported by findings from the phase 3 C-POST trial (NCT03969004), in which cemiplimab reduced the risk of recurrence or death by 68% vs placebo (HR, 0.32; 95% CI, 0.20-0.51; P < .0001), with median disease-free survival not reached in the cemiplimab arm. Recurrence occurred in 9% of patients in the cemiplimab arm vs 30% of those in the placebo arm. The toxicity profile was consistent with prior findings, with common adverse effects (AEs) including rash, pruritus, and hypothyroidism. The decision signifies the first and only immunotherapy approved for adjuvant treatment in those with CSCC with a high risk of recurrence following surgery and radiation.

The FDA has issued a complete response letter (CRL) to the new drug application (NDA) for dasatinib (Dasynoc) for use in patients with chronic myeloid leukemia (CML). The CRL stems from Good Manufacturing Practice observations at the company’s contract manufacturing site, prompting a temporary pause in new product approvals until corrective actions are completed. The manufacturer has begun remediation efforts and plans to meet with the regulatory agency later this year to address outstanding issues. The NDA for dasatinib sought approval for a formulation designed to maintain efficacy at lower doses, reduce pharmacokinetic variability, and minimize drug-drug interactions associated with acid-suppressive agents. Despite manufacturing delays, the drug remains under active development, with plans for expedited resubmission once compliance measures are met.

The regulatory agency also accepted and granted priority review to the biologics license application (BLA) seeking approval of Orca-T for select patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplastic syndrome (MDS). The application is supported by data from the phase 3 Precision-T trial (NCT04013685), in which Orca-T significantly improved 1-year moderate-to-severe chronic graft-vs-host disease (cGVHD)–free survival vs conventional allogeneic hematopoietic stem cell transplant (allo-HSCT; 78% vs 38%; HR, 0.26; P < .00001). Those who received Orca-T also experienced lower rates of moderate-to-severe cGVHD (13% vs 44%) and grade 3/4 acute GVHD (6% vs 17%) vs allo-HSCT. One-year overall survival (OS) was 94% in the Orca-T arm and 83% in the allo-HSCT arm, and non-relapse mortality rates were 3% vs 13%, respectively. The target action date for the BLA is set for April 6, 2026.

Data from the phase 3 TROPION-Breast02 trial (NCT05374512) showed that datopotamab deruxtecan-dlnk (Dato-DXd; Datroway) significantly improved OS and progression-free survival (PFS) vs investigator’s choice of chemotherapy in patients with locally recurrent, inoperable, or metastatic triple-negative breast cancer (TNBC) not able to receive immunotherapy. The safety profile of Dato-DXd was consistent with prior breast cancer studies. AstraZeneca and Daiichi Sankyo will share these results with regulatory authorities, highlighting the potential of the antibody-drug conjugate as the first therapy to significantly improve OS in this population.

The FDA has granted fast track designation to the TEAD autopalmitoylation inhibitor VT3989 for use in patients with unresectable malignant pleural or non-pleural mesothelioma who have progressed after previous immune checkpoint inhibition and platinum-based chemotherapy. Preliminary findings from an ongoing phase 1/2 trial (NCT04665206) demonstrated that the agent led to reductions in target lesion size in both pleural and non-pleural mesothelioma, irrespective of NF2 mutational status. The multicenter trial includes dose-escalation, dose-expansion, and combination cohorts, which are evaluating safety, antitumor activity, and pharmacokinetics of the agent, with oral dosing ranging from 25 mg to 200 mg. Common treatment-related AEs included albuminuria, proteinuria, fatigue, peripheral edema, and gastrointestinal and hepatic effects.

Honorable Mentions

• OncLive spoke with the following leading genitourinary oncology experts to highlight the most anticipated abstracts and data at the 2025 ESMO Congress: David A. Braun, MD, PhD, of Yale Medical School; Alan Tan, MD, of Vanderbilt University Medical Center; and Axel Merseburger, MD, PhD, of University Hospital Schleswig-Holstein. Check out the exclusive preview ahead of the meeting.
• From further clarifying the role of PD-(L)1 inhibition in gastric cancer and colorectal cancer, to demonstrating the potential predictive value of minimal residual disease negativity in late-stage colon cancer, gastrointestinal oncology data presented at the 2025 ESMO Congress are anticipated to challenge current standards of care and bring new questions to the forefront of research in the field. In this exclusive preview, Tanios S. Bekaii-Saab, MD, of Mayo Clinic; Suneel Kamath, MD, of Cleveland Clinic Lerner College of Medicine of Case Western Reserve University; and Kanwal P. S. Raghav, MBBS, MD, of The University of Texas MD Anderson Cancer Center, share their most anticipated abstracts.

Less than 10 years after dropping out of New York University and then starting what would become the prediction market Polymarket in the bathroom of his Lower East Side apartment, Shayne Coplan has been crowned the youngest ever self-made billionaire by capitalizing on Gen Z’s readiness to bet on anything.

On Tuesday, the New York Stock Exchange’s parent company, Intercontinental Exchange, invested $2 billion cash in Polymarket, skyrocketing the company’s valuation to $9 billion post investment and making CEO and founder Coplan a billionaire at the age of 27, according to the Bloomberg Billionaire Index.

Through the partnership, the NYSE will distribute Polymarket’s data and the two companies will work together on tokenization initiatives, according to a press release.

Polymarket has a simple premise: Markets are the best way to source truth. By giving users a stake in predicting literally everything, from the 2025 World Series Champion to when the government shutdown will end (both bets are currently available on its website), Polymarket aims to “harness the power of free markets to demystify real events that matter most to you,” Coplan said in a post on X.

Polymarket matches users with opposing bets and pays out $1 per “share” for every correct guess with the help of a U.S. dollar-backed stablecoin and a blockchain built on top of Ethereum’s infrastructure. This means if you bet “yes” on an outcome at 37 cents and it proves to be true, you’ll net a 63-cent profit. You can also sell your stake in an outcome before the event happens, which can also net you a profit if the price of your shares go up as the outcome you chose becomes more likely.

Aleksandar Tomic, an economist and associate dean for strategy, innovation, and technology at Boston College, said prediction markets like Polymarket have existed before. A similar platform, Intrade, received widespread media attention for its success in predicting the 2008 and 2012 U.S. elections before shutting down in 2013. Polymarket and its competitors seem to be succeeding where others have failed. Polymarket for its part has drawn in younger users with a better platform and by seizing upon the pandemic-era gambling trend especially prevalent in Gen Z men—not to mention with a little help from a newly friendly regulatory environment.

“I think these types of markets are just another place to make a bet,” Tomic told Fortune.

Polymarket did not immediately respond to a request for comment.

Until last month, Polymarket was banned in the U.S., largely due to federal regulators’ objections to its “speed over scrutiny” business model. In 2022, the company paid a $1.4 million fine after the Commodity Futures Trading Commission (CFTC) said it was allegedly operating an unregistered event market. The platform was subsequently barred from the country. As wagers on the 2024 election grew last year, the CFTC renewed its scrutiny, and the FBI raided founder Shayne Coplan’s home in November. Just under a year later—following President Trump’s return to office, and with Donald Trump Jr. now serving as an adviser to the company—the CFTC and Justice Department closed their investigations without filing charges, clearing the way for Polymarket’s return to the U.S.

Despite Polymarket’s many headwinds over the years, Coplan has previously pointed out some of the company’s notable successes on X, including predicting that President Biden would drop out of the 2024 presidential election. In total, Polymarket users put at least $3.2 billion into the presidential election, and one French trader even made around $85 million from his contrarian multimillion-dollar bet that President Donald Trump would return to the Oval Office.

With this week’s announcement of the team-up and investment from the New York Stock Exchange’s parent company, Coplan is riding high, while still reflecting on his journey upwards.

“At the onset of the pandemic, I quite literally had nothing to lose: 21, running out of money, 2.5 years since I dropped out and nothing to show for it,” he wrote on X. “But I knew we were entering an era where ways to find truth would matter more than ever, and Polymarket could play a critical role in that.”

On Sunday, he plans to watch football and beta-test the new Polymarket U.S. app, he wrote on X.

This story was originally featured on Fortune.com

Being a dedicated sort, I tasted all 10 of these mustards straight from the jar. With watering eyes, pumping endorphins and overactive salivary glands, I licked each mustard off a spoon, then quickly cleansed my palate with plenty of milk and water to subdue the heat. But the sandwich I had at the end, with my new favourite mustard, was worth every fiery spoonful.

Mustard is intriguingly complex in flavour – powerful, umami, hot – yet easy to make. At its simplest, it is little more than fermented mustard seeds soaked in brine until viscous and bubbling. Sadly, however, many modern brands, especially the cheaper ones, see fit to include unnecessary additives, such as xanthan gum and wheat flour. And, rather predictably, the cheaper the mustard, the less actual mustard it tends to contain.

Much as with mayonnaise, many processed mustards contain spirit vinegar instead of more subtle acids, such as white-wine or cider vinegar. Spirit vinegar is harsh and sharp, dominates the overall flavour and can result in an unappealingly aerated, mousse-like texture. In fact, six of the mustards I tasted were so similar, I wouldn’t be at all surprised if they were all made in the same factory. They were essentially carbon copies of each other – sulphuric, sweet, hot and moussey – even if they did still bear the hallmark fieriness and complexity of a classic English mustard.

So, when looking for a mustard that’s worth your money, seek out those with real vinegar rather than spirit vinegar, and without emulsifiers or texturing agents such as wheat flour; they’re simply unnecessary. Or, better still, make your own: you can easily produce a year’s worth of mustard with just five minutes’ work.

The best supermarket English mustard

Best overall:
Stokes classic English mustard